ClinVar Miner

Submissions for variant NM_000169.3(GLA):c.707G>A (p.Trp236Ter)

dbSNP: rs879254022
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 5
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000235716 SCV000293199 pathogenic not provided 2015-09-24 criteria provided, single submitter clinical testing The W236X nonsense variant in the GLA gene has been reported previously in association with Fabry disease (Jojart et al., 2009; Germain et al., 2002), and its presence is consistent with the diagnosis in the patient. This mutation is predicted to cause loss of normal protein function either through protein truncation or nonsense-mediated mRNA decay. Approximately 60-70% of females with a single GLA mutation have some disease manifestations, and 10% of these individuals present with a disease severity that is similar to that of affected males (Bennett et al., 2002).
Invitae RCV000692369 SCV000820189 pathogenic Fabry disease 2021-09-20 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Trp236*) in the GLA gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in GLA are known to be pathogenic (PMID: 10666480, 12175777). For these reasons, this variant has been classified as Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. ClinVar contains an entry for this variant (Variation ID: 245967). This premature translational stop signal has been observed in individuals with classic Fabry disease (PMID: 12428061, 27560961). This variant is not present in population databases (ExAC no frequency).
Revvity Omics, Revvity RCV000235716 SCV002024326 pathogenic not provided 2019-08-19 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV000692369 SCV002054417 pathogenic Fabry disease 2021-07-15 criteria provided, single submitter clinical testing
CeGaT Center for Human Genetics Tuebingen RCV000235716 SCV005092638 pathogenic not provided 2024-07-01 criteria provided, single submitter clinical testing GLA: PVS1, PM2, PS4:Moderate

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.